Patents by Inventor Guillaume El Glaoui
Guillaume El Glaoui has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11951095Abstract: The present invention relates to non-hormonal compositions and methods for inducing a condition of aspermia, azoospermia, or severe oligozoospermia in the male subject such that these compositions and methods for administering the same may be used as male contraception. Embodiments of the present invention may comprise a composition comprising an alpha-1-adrenoreceptor antagonist, such as (R)-silodosin, for daily administration to a male subject. The compositions and related methods may further include pharmaceutically acceptable carriers. The present invention further includes formulations which allow for a delay such that delayed or missed dose(s) do not nullify the contraceptive effect of the treatment regimen. Such compositions and methods may also avoid the side effects associated with typical formulations of alpha-1-adrenoreceptor antagonists.Type: GrantFiled: January 6, 2023Date of Patent: April 9, 2024Assignee: PHARMAJOR INTERNATIONALInventors: Guillaume El Glaoui, Mehdi El Glaoui, Philippe Perrin, Stéphane Droupy, Véronique Agathon-Meriau
-
Publication number: 20230145374Abstract: The present invention relates to non-hormonal compositions and methods for inducing a condition of aspermia, azoospermia, or severe oligozoospermia in the male subject such that these compositions and methods for administering the same may be used as male contraception. Embodiments of the present invention may comprise a composition comprising an alpha-1-adrenoreceptor antagonist, such as (R)-silodosin, for daily administration to a male subject. The compositions and related methods may further include pharmaceutically acceptable carriers. The present invention further includes formulations which allow for a delay such that delayed or missed dose(s) do not nullify the contraceptive effect of the treatment regimen. Such compositions and methods may also avoid the side effects associated with typical formulations of alpha-1-adrenoreceptor antagonists.Type: ApplicationFiled: January 6, 2023Publication date: May 11, 2023Applicant: PHARMAJOR INTERNATIONALInventors: Guillaume EL GLAOUI, Mehdi EL GLAOUI, Philippe PERRIN, Stéphane DROUPY, Véronique AGATHON-MERIAU
-
Patent number: 11583518Abstract: The present invention relates to non-hormonal compositions and methods for inducing a condition of aspermia, azoospermia, or severe oligozoospermia in the male subject such that these compositions and methods for administering the same may be used as male contraception. Embodiments of the present invention may comprise a composition comprising an alpha-1-adrenoreceptor antagonist, such as (R)-silodosin, for daily administration to a male subject. The compositions and related methods may further include pharmaceutically acceptable carriers. The present invention further includes formulations which allow for a delay such that delayed or missed dose(s) do not nullify the contraceptive effect of the treatment regimen. Such compositions and methods may also avoid the side effects associated with typical formulations of alpha-1-adrenoreceptor antagonists.Type: GrantFiled: December 30, 2020Date of Patent: February 21, 2023Assignee: PHARMAJOR INTERNATIONALInventors: Guillaume El Glaoui, Mehdi El Glaoui, Philippe Perrin, Stéphane Droupy, Véronique Agathon-Meriau
-
Publication number: 20210113526Abstract: The present invention relates to non-hormonal compositions and methods for inducing a condition of aspermia, azoospermia, or severe oligozoospermia in the male subject such that these compositions and methods for administering the same may be used as male contraception. Embodiments of the present invention may comprise a composition comprising an alpha-1-adrenoreceptor antagonist, such as (R)-silodosin, for daily administration to a male subject. The compositions and related methods may further include pharmaceutically acceptable carriers. The present invention further includes formulations which allow for a delay such that delayed or missed dose(s) do not nullify the contraceptive effect of the treatment regimen. Such compositions and methods may also avoid the side effects associated with typical formulations of alpha-1-adrenoreceptor antagonists.Type: ApplicationFiled: December 30, 2020Publication date: April 22, 2021Applicant: LABORATOIRES MAJORInventors: Guillaume EL GLAOUI, Mehdi EL GLAOUI, Philippe PERRIN, Stéphane DROUPY, Véronique AGATHON-MERIAU
-
Patent number: 10912762Abstract: The present invention relates to non-hormonal compositions and methods for inducing a condition of aspermia, azoospermia, or severe oligozoospermia in the male subject such that these compositions and methods for administering the same may be used as male contraception. Embodiments of the present invention may comprise a composition comprising an alpha-1-adrenoreceptor antagonist, such as (R)-silodosin, for daily administration to a male subject. The compositions and related methods may further include pharmaceutically acceptable carriers. The present invention further includes formulations which allow for a delay such that delayed or missed dose(s) do not nullify the contraceptive effect of the treatment regimen. Such compositions and methods may also avoid the side effects associated with typical formulations of alpha-1-adrenoreceptor antagonists.Type: GrantFiled: March 22, 2019Date of Patent: February 9, 2021Assignee: LABORATOIRES MAJORInventors: Guillaume El Glaoui, Mehdi El Glaoui, Philippe Perrin, Stéphane Droupy, Véronique Agathon-Meriau
-
Publication number: 20190290615Abstract: The present invention relates to non-hormonal compositions and methods for inducing a condition of aspermia, azoospermia, or severe oligozoospermia in the male subject such that these compositions and methods for administering the same may be used as male contraception. Embodiments of the present invention may comprise a composition comprising an alpha-1-adrenoreceptor antagonist, such as (R)-silodosin, for daily administration to a male subject. The compositions and related methods may further include pharmaceutically acceptable carriers. The present invention further includes formulations which allow for a delay such that delayed or missed dose(s) do not nullify the contraceptive effect of the treatment regimen. Such compositions and methods may also avoid the side effects associated with typical formulations of alpha-1-adrenoreceptor antagonists.Type: ApplicationFiled: March 22, 2019Publication date: September 26, 2019Applicant: LABORATOIRES MAJORInventors: Guillaume El GLAOUI, Mehdi El GLAOUI, Philippe PERRIN, Stéphane DROUPY, Véronique AGATHON-MERIAU
-
Patent number: 9233050Abstract: The device (1) according to the invention aims to join at least two medicine capsules (A, B) by adhesive bonding in a reliable and economical manner, in particular in the context of industrial production. To do this, this device comprises at least one matrix (10), which at least partially delimits a recess (15), for depositing capsules (Eight, B), and also a chamber (16), this recess and this chamber being separated from each other by a deformable wall (14) of the matrix, which matrix is designed to move elastically, by pneumatic action of its chamber (16), from a first configuration, in which its recess (15) receives the capsules with a glue (Z) interposed between them, to a second configuration, in which its deformable wall (14) at least partially envelops the capsules by flexible deformation, in such a way as to at least partially enclosed these capsules between the deformable wall and a bottom of the recess in order to align them and press them against one another.Type: GrantFiled: July 12, 2011Date of Patent: January 12, 2016Assignee: DUO-GEInventors: Mehdi El Glaoui, Guillaume El Glaoui, Jean Hoffelt, Jean-Pierre Fontaine
-
Publication number: 20160000715Abstract: An oral pharmaceutical dosage form is provided which contains at least two medicaments, in which form the medicaments on the one hand are brought together in a leakproof and in-vivo water soluble wrapping and on the other hand are separated so that the active principle of the combined medicaments cannot come into contact with one another. At least one of the medicaments can be chosen from the following therapeutic classes: non-steroidal anti-inflammatory drug (NSAID), proton pump inhibitor (PPI), beta-blocker, statin, conversion enzyme inhibitor (CEI), biguanide, myorelaxant, calcium inhibitor, corticoid, antidepressant, benzodiazepine, non-atropine-like intestinal transit retarder, intestinal antibacterial, and the following therapeutic molecules: spironolactone, propranolol, clarithromycin, amoxycillin, low-dose acetylsalicylic acid, potassium, and clopidogrel.Type: ApplicationFiled: April 3, 2015Publication date: January 7, 2016Inventors: Anne-Emmanuelle LUGRIN, Claude GRISCELLI, Mehdi EL GLAOUI, Guillaume EL GLAOUI, Jean HOFFELT
-
Publication number: 20140008025Abstract: The device (1) according to the invention aims to join at least two medicine capsules (A, B) by adhesive bonding in a reliable and economical manner, in particular in the context of industrial production. To do this, this device comprises at least one matrix (10), which at least partially delimits a recess (15), for depositing capsules (Eight, B), and also a chamber (16), this recess and this chamber being separated from each other by a deformable wall (14) of the matrix, which matrix is designed to move elastically, by pneumatic action of its chamber (16), from a first configuration, in which its recess (15) receives the capsules with a glue (Z) interposed between them, to a second configuration, in which its deformable wall (14) at least partially envelops the capsules by flexible deformation, in such a way as to at least partially enclosed these capsules between the deformable wall and a bottom of the recess in order to align them and press them against one another.Type: ApplicationFiled: July 12, 2011Publication date: January 9, 2014Applicant: DUO-GEInventors: Mehdi El Glaoui, Guillaume El Glaoui, Jean Hoffelt, Jean-Pierre Fontaine
-
Publication number: 20130237504Abstract: Methods for selecting active principles to be used in association within a single pharmaceutical form, the method comprising searching, selecting and analyzing published bibliographic data. The disclosure also relates computer-implemented methods for selecting active principles to be used in association within a single pharmaceutical form, comprising: selecting with a processor-implemented process at least one listing of keywords stored in memory; and submitting the keywords in a query. Further, the specification relates to pharmaceutical oral forms defined by implementing these methods, wherein at least two active principles are brought together in a leak proof water-soluble wrapping or envelop and the active principles cannot come into contact with one another.Type: ApplicationFiled: March 12, 2012Publication date: September 12, 2013Inventors: Mehdi El Glaoui, Guillaume El Glaoui, Antoine Ferry, Anne-Emmanuelle Lugrin, Jean-Pierre Boissel
-
Publication number: 20110027356Abstract: Oral pharmaceutical dosage form containing at least two medicaments, in which form the medicaments on the one hand are brought together in a leakproof and in-vivo water soluble wrapping and on the other hand are separated so that the active principle of the combined medicaments cannot come into contact with one another, at least one of the medicaments being selected from the following therapeutic classes: non-steroidal anti-inflammatory drug (NSAID), proton pump inhibitor (PPI), beta-blocker, statin, conversion enzyme inhibitor (CEI), biguanide, myorelaxant, calcium inhibitor, corticoid, antidepressant, benzodiazepine, non-atropine-like intestinal transit retarder, intestinal antibacterial, and the following therapeutic molecules: spironolactone, propranolol, clarithromycin, amoxycillin, low-dose acetylsalicylic acid, potassium, clopidogrel.Type: ApplicationFiled: January 26, 2009Publication date: February 3, 2011Inventors: Anne-Emmanuelle Lugrin, Claude Griscelli, Mehdi El Glaoui, Guillaume El Glaoui, Jean Hoffelt